Read More Pharma Industry News Will Avacta’s pre|CISION platform turn its £3.25m bond repayment into a precision oncology breakthrough? Avacta Group plc raises £3.25M to repay its convertible bond and extend clinical runway for its pre|CISION cancer drugs—find out what’s next. byPallavi MadhirajuJuly 20, 2025